Cancer-associated fibroblast subtype signature gene predicts survival and immunotherapy response in sarcoma
PLOS One · 20.07.2026 · 21 (7) · e0353369
DOI: 10.1371/journal.pone.0353369 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 20.07.2026. Verfasst von Ji-Yong Sung und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, College of Natural Sciences, Seoul National University, Seoul, South Korea. Hauptthemen laut MEDLINE: Sarcoma, Immunotherapy, Cancer-Associated Fibroblasts. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, National R&D Program for Cancer Control, Ministry of Health and Welfare, the Korea Health Technology R&D Project through the Korea Health Industry Development Institute.
Abstract (Originalsprache)
Background
Sarcomas show heterogeneous responses to immune-checkpoint blockade (ICB), and cancer-associated fibroblasts (CAFs) are considered to shape the tumor immune microenvironment, yet CAF programs that predict ICB outcomes in sarcoma remain unclear.
Methods
We investigated the interaction between different cell types in the sarcoma tumor microenvironment and their effects on immune-checkpoint blockade response, with a focus on identifying signature genes and molecular mechanisms that distinguish tumor-promoting from tumor-suppressive CAFs at the single-cell level. We analyzed single-cell data from two different sarcoma cohorts, transcriptome profiles of 206 sarcoma patients recruited from The Cancer Genome Atlas, and predicted immune-checkpoint blockade (ICB) response data inferred using the TIDE algorithm from 64 TCGA sarcoma patients.
Results
We found 134 stem-like CAF-related signature genes in the recurrent group and eight signature genes in the metastasis group, defining three CAF subtypes (myofibroblastic CAF, antigen-presenting CAF, and inflammatory CAF). SIG134 and SIG8 were associated with TIDE-inferred ICB response in subtype-specific analyses: SIG134 in STLMS and ULMS, and SIG8 in MFS, STLMS, and ULMS. In addition, the MDK-NCL ligand-receptor signal transduction pathway was linked to the infCAF subtype and myoCAFs in metastatic sarcoma. Furthermore, SIG4 ( MDK , SDC2 , LRP1 , and NCL ) was highly expressed in inflammatory CAFs.
Conclusions
Single-cell-derived CAF signatures may reflect sarcoma subtype-specific stromal programs associated with predicted ICB response and clinical outcome. SIG4 is proposed as a candidate prognostic signature that warrants further validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences, College of Natural Sciences, Seoul National University, Seoul, South Korea.
- Department of Occupational and Environmental Medicine, College of Medicine, Ewha Womans University, Seoul, South Korea.
- Graduate Program in System Health Science and Engineering, Ewha Womans University, Ewha Medical Research Institute, College of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Yi-Jun Kim
Förderung
- National Research Foundation of Korea
- National R&D Program for Cancer Control, Ministry of Health and Welfare
- the Korea Health Technology R&D Project through the Korea Health Industry Development Institute
Zitieren
APA
Sung, J. Y., Kim, J. H., & Kim, Y. J. (2026). Cancer-associated fibroblast subtype signature gene predicts survival and immunotherapy response in sarcoma. PLOS One, 21(7), e0353369. https://doi.org/10.1371/journal.pone.0353369
Vancouver
Sung JY, Kim JH, Kim YJ. Cancer-associated fibroblast subtype signature gene predicts survival and immunotherapy response in sarcoma. PLOS One. 2026;21(7):e0353369. doi:10.1371/journal.pone.0353369
BibTeX
@article{Sung2026,
author = {Sung, Ji-Yong and Kim, Jin-Hong and Kim, Yi-Jun},
title = {Cancer-associated fibroblast subtype signature gene predicts survival and immunotherapy response in sarcoma},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {7},
pages = {e0353369},
doi = {10.1371/journal.pone.0353369}
}
EUVIMED